

**Type the Title of Your Manuscript Here (Sentence Case, Not More Than 20**

**Words, Times New Roman 14 pt, Bold, Centered)**

**First Author<sup>1,\*</sup>, Second Author<sup>1,2</sup>, Third Author<sup>2</sup>**

<sup>1</sup>Department A, Faculty A, University A, City A, Country A

<sup>2</sup>Department A, Faculty A, University A, City A, Country A

<sup>3</sup> Department A, Faculty A, University A, City A, Country A

\*Corresponding Author. Email: [typeyouremail@here.com](mailto:typeyouremail@here.com)

Mobile Number: (+62) 0812345678

---

---

### ***ABSTRACT***

*Written in one paragraph with less than 250 words, Times New Roman 11 pt, justified, contains the brief description of:*

***Background:***

***Content:***

***Summary:***

***Keywords:*** Cattle; import; indigenous; malaria; Plasmodium sp

*Keywords contain 3-6 words/or short phrases (capital letters only found in the first keyword, separated by semicolons (;) and not ending periods in the last keyword).*

*The use of keywords should be adjusted to MeSH ◇ check the keywords used, use the web <https://meshb.nlm.nih.gov/MeSHonDemand>*

## INTRODUCTION

The content of introduction usually is the background of research, position of the research towards the other similar research. It can be a brief literature review. It is written using Times New Roman 12 with 1,5 space and each new paragraph with spacing 6pt. Reference cited according to Vancouver. In writing the citations and references, authors are recommended to use Mendeley® reference management software.

### SUBHEADING 1 (CASE)

This section provides case details in the following order: patient description, case history, physical examination findings, pathological test results and other investigations, treatment plan, expected treatment outcomes, and actual outcomes. It is written using Times New Roman 12 pt with 1,5 space and each new paragraph with spacing 6pt.

### SUBHEADING 2

Decimal fractions should be written in English format (use commas for thousands and periods for decimals). Drug names should use generic names. When proprietary brand names are used in the study, include the brand name, manufacturer's name, and location (city & country) in parentheses after the first mention of the generic name. To support your review, you may include tables or figures with proper references.

For better structure, include only one idea or aspect per paragraph. Avoid citing just one study in a paragraph; instead, consider incorporating several studies in one paragraph.


It is written using Times New Roman 12 with 1,5 space and each new paragraph with spacing 6pt.

Type your table caption with 11-point Times New Roman font and single space. Number tables consecutively in accordance with their appearance in the text. Present the table with no vertical lines. If you use raw data, not the modified one, please provide proof of permission that has been obtained to reproduce the data from other publications.

**Table 1. Comparison of cardiac function tests levels between control and sickle cell trait patients: (mean±SD)**

Parameter	Value
Parameter a (unit)	Mean±SD
Parameter b (unit)	Mean±SD
Parameter c (unit)	Mean±SD

Source: Author, year (Written in Times New Roman 11 italic)



**Figure 1. Pathway of Cardiac Hypertrophy<sup>23</sup>**

(Should be written in Times New Roman 11 with single space and place below the figure directly)

## DISCUSSION

This section should begin by expanding on what was introduced in the introduction, focusing on why this case is important and the issues it addresses. This is followed by a summary of the existing literature on the topic. The section should explain current theories and research findings related to the main issues in the patient's condition.

The review should be narrowed down to the main sources of confusion or challenges in this case. Finally, the case report should be connected to the existing literature, highlighting the key message conveyed by this case. Authors should explain whether this strengthens or weakens current understanding of the issue and how this evidence could add value to future clinical practice.

References used should primarily be from the last 5 years to ensure updated and relevant discussion.

## CONCLUSION

The conclusion should summarize the findings and discussion in relation to the study objectives. It should provide an answer to the research question, expressed in flowing paragraphs rather than in statistical sentences. Use meaningful scientific terms in the field of study and avoid overly technical statistical/methodological jargon.

## Conflicts of Interest

Generated from the conflict of interest forms by each author. The form provided in <http://www.icmje.org/conflicts-of-interest/>.

## Funding Sources

## Acknowledgements

Personal acknowledgments should be limited to appropriate professionals who contributed to the paper, including technical help and financial or material support, also general support by a department chairperson.

## REFERENCES

The references must be written in accordance with the **Vancouver style and managed using Mendeley® reference management software**. All references in the bibliography should be numbered consecutively based on their appearance in the article, not in alphabetical order. Only references that are used and relevant (up-to-date and reputable) should be included.

A minimum of 80% of the references must consist of primary sources, published **within the last five years**. Articles published in this journal are recommended to be cited as

references. The total number of references **must exceed 15 sources**.

1. Sandra F, Esposti MD, Ndebele K, Gona P, Knight D, Rosenquist M, *et al*. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Alters Mitochondrial Membrane Lipids. *Cancer Res*. 2005; 65: 8286-97.
2. Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. *Medical microbiology*. 4th ed. St. Louis: Mosby; 2002.
3. Rosenberg GA. Matrix metalloproteinase and proteolytic opening of the blood brain-barrier in neuroinflammation. In: deVries E, Prat A, editors. *The Blood-brain Barrier and Its Microenvironment Basic Physiology to Neurological Disease*. New York: Taylor and Francis Group; 2005. p.335-58.
4. Arlauckas SP. Near infrared fluorescent choline kinase alpha inhibitors for cancer imaging and therapy [Dissertation]. Philadelphia: University of Pennsylvania; 2015.
5. Medline Plus [Internet]. Bethesda: US National Library of Medicine; ©2009. Diabetic Kidney Problems [update 2015 Nov 2; cited 2015 Nov 16]. Available from: <https://www.nlm.nih.gov/medlineplus/diabetickidneyproblems.html/>.
6. Fledelius HS. Myopia and significant visual impairment: global aspects. In: Lin LLK, Shin YF, Hung PT, editors. *Myopia Updates II: Proceedings of the 7th International Conference on Myopia 1998 Nov 17-20, Taipei*. Tokyo: Springer; 2000. p.3-17.